Lenvatinib mesylate
产品说明书
 |
同义名 : | 乐伐替尼甲磺酸盐 ;E7080 mesylate; Lenvatinib (mesylate); E-7080 |
| CAS号 : | 857890-39-2 | |
| 货号 : | A283982 | |
| 分子式 : | C22H23ClN4O7S | |
| 纯度 : | 99% | |
| 分子量 : | 522.96 | |
| MDL号 : | - | |
| 存储条件： |
Pure form Inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Lenvatinib mesylate (E7080 mesylate) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor 1-3, vascular endothelial growth factor receptor 1-4, epidermal growth factor receptor, KIT, and RET, showing potent antitumour activity[1][2].The IC50 of Lenvatinib mesylate against VEGFR2, VEGFR3, and VEGFR1 was 4, 5.2, and 22 nM, respectively.The IC50 of Lenvatinib mesylate for inhibition of PDGFRα, PDGFRβ, FGFR1, and KIT was 51, 39, 46, and 100 nM, respectively[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.91mL 0.38mL 0.19mL |
9.56mL 1.91mL 0.96mL |
19.12mL 3.82mL 1.91mL |
